Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis

Molecular Therapy

Volumn 18, Issue 6, 2010, Pages 1233-1243

  Chen, Chi An ^a   Ho, Chih Ming ^b   Chang, Ming Cheng ^a   Sun, Wei Zun ^a   Chen, Yu Li ^a   Chiang, Ying Cheng ^a   Syu, Ming Hong ^a   Hsieh, Chang Yao ^a   Cheng, Wen Fang ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR LINKED TO THE TUMOR ANTIGEN HUMAN PAPILLOMAVIRUS 16 E7; DNA VACCINE; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CANCER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENTIATION; IMMUNOMODULATION; LOW DRUG DOSE; LUNG TUMOR; METASTASIS; MOUSE; NONHUMAN; T CELL DEPLETION; TUMOR VASCULARIZATION; ANIMAL; HUMAN; IMMUNOLOGY; LYMPHOCYTE DEPLETION; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); REGULATORY T LYMPHOCYTE; VASCULARIZATION;

HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; HUMANS; LYMPHOCYTE DEPLETION; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; T-LYMPHOCYTES, REGULATORY;

EID: 77953134540     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.34     Document Type: Article

References (47)

1. Boon, T, Cerottini, JC, Van den Eynde, B, van der Bruggen, P and Van Pel, A (1994). Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365.
2. Nigam, A, Yacavone, RF, Zahurak, ML, Johns, CM, Pardoll, DM, Piantadosi, S et al. (1998). Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 12: 161-170.
3. Proietti, E, Greco, G, Garrone, B, Baccarini, S, Mauri, C, Venditti, M et al. (1998). Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 101: 429-441.
4. Kerbel, RS, Klement, G, Pritchard, KI and Kamen, B (2002). Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13: 12-15.
5. Mekhail, TM and Markman, M (2002). Paclitaxel in cancer therapy. Expert Opin Pharmacother 3: 755-766.
6. Moore, HC, Green, SJ, Gralow, JR, Bearman, SI, Lew, D, Barlow, WE et al. (2007). Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol 25: 1677-1682.
7. Sorger, PK, Dobles, M, Tournebize, R and Hyman, AA (1997). Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 9: 807-814.
8. Slichenmyer, WJ and Von Hoff, DD (1990). New natural products in cancer chemotherapy. J Clin Pharmacol 30: 770-788.
9. Manthey, CL, Brandes, ME, Perera, PY and Vogel, SN (1992). Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol 149: 2459-2465.
10. Rowinsky, EK, Onetto, N, Canetta, RM and Arbuck, SG (1992). Taxol: the frst of the taxanes, an important new class of antitumor agents. Semin Oncol 19: 646-662.
11. Pasquier, E, Honore, S, Pourroy, B, Jordan, MA, Lehmann, M, Briand, C et al. (2005). Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65: 2433-2440.
12. Klauber, N, Parangi, S, Flynn, E, Hamel, E and D'Amato, RJ (1997). Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86.
13. Cheng, WF, Lee, CN, Su, YN, Chang, MC, Hsiao, WC, Chen, CA et al. (2005). Induction of human papillomavirus type 16-specifc immunologic responses in a normal and an human papillomavirus-infected populations. Immunology 115: 136-149.
14. Disis, ML and Schiffman, K (2001). Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28(6 Suppl 18): 12-20.
15. Antonia, SJ, Seigne, J, Diaz, J, Muro-Cacho, C, Extermann, M, Farmelo, MJ et al. (2002). Phase I trial of a B7-1 (CD80) gene modifed autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167: 1995-2000.
16. Sondak, VK, Liu, PY, Tuthill, RJ, Kempf, RA, Unger, JM, Sosman, JA et al. (2002). Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20: 2058-2066.
17. Kim, TW, Lee, JH, He, L, Boyd, DA, Hardwick, JM, Hung, CF et al. (2005). Modifcation of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65: 309-316.
18. Hsieh, CY, Chen, CA, Huang, CY, Chang, MC, Lee, CN, Su, YN et al. (2007). IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol Ther 15: 1890-1897.
19. Cheng, WF, Hung, CF, Chai, CY, Hsu, KF, He, L, Ling, M et al. (2001). Tumor-specifc immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-678. (Pubitemid 32906195)
20. Gorelick, RJ, Benveniste, RE, Gagliardi, TD, Wiltrout, TA, Busch, LK, Bosche, WJ et al. (1999). Nucleocapsid protein zinc-fnger mutants of simian immunodefciency virus strain mne produce virions that are replication defective in vitro and in vivo. Virology 253: 259-270.
21. Bello, L, Carrabba, G, Giussani, C, Lucini, V, Cerutti, F, Scaglione, F et al. (2001). Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61: 7501-7506.
22. Bertolini, F, Paul, S, Mancuso, P, Monestiroli, S, Gobbi, A, Shaked, Y et al. (2003). Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346.
23. Cheng, WF, Hung, CF, Lin, KY, Ling, M, Juang, J, He, L et al. (2003). CD8+ T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 10: 1311-1320.
24. Hung, CF, Cheng, WF, He, L, Ling, M, Juang, J, Lin, CT et al. (2003). Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 63: 2393-2398.
25. Nowak, AK, Robinson, BW and Lake, RA (2003). Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490-4496.
26. Welt, S, Ritter, G, Williams, C Jr, Cohen, LS, Jungbluth, A, Richards, EA et al. (2003). Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 9: 1347-1353.
27. Eralp, Y, Wang, X, Wang, J P, Maughan, MF, Polo, JM and Lachman, LB (2004). Doxorubicin and paclitaxel enhance the antitumor effcacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 6: R275-R283.
28. Berd, D, Maguire, HC Jr and Mastrangelo, MJ (1986). Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572-2577.
29. Degl'Innocenti, E, Grioni, M, Capuano, G, Jachetti, E, Freschi, M, Bertilaccio, MT et al. (2008). Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res 68: 292-300.
30. Curiel, TJ, Coukos, G, Zou, L, Alvarez, X, Cheng, P, Mottram, P et al. (2004). Specifc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
31. Powell, DJ Jr, Felipe-Silva, A, Merino, MJ, Ahmadzadeh, M, Allen, T, Levy, C et al. (2007). Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 179: 4919-4928.
32. Phan, GQ, Yang, JC, Sherry, RM, Hwu, P, Topalian, SL, Schwartzentruber, DJ et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377.
33. Kudo-Saito, C, Schlom, J, Camphausen, K, Coleman, CN and Hodge, JW (2005). The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 11: 4533-4544.
34. Audia, S, Nicolas, A, Cathelin, D, Larmonier, N, Ferrand, C, Foucher, P et al. (2007). Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 150: 523-530.
35. Ghiringhelli, F, Menard, C, Puig, PE, Ladoire, S, Roux, S, Martin, F et al. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648.
36. Drevs, J, Fakler, J, Eisele, S, Medinger, M, Bing, G, Esser, N et al. (2004). Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24(3a): 1759-1763.
37. Yoshida, S, Nomoto, K, Himeno, K and Takeya, K (1979). Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice. Clin Exp Immunol 38: 211-217.
38. Lin, K Y, Guarnieri, FG, Staveley-O'Carroll, K F, Levitsky, HI, August, JT, Pardoll, DM et al. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26.
39. Cheng, WF, Chang, MC, Sun, WZ, Lee, CN, Lin, HW, Su, YN et al. (2008). Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Ther 15: 1007-1016.
40. Liao, CW, Chen, CA, Lee, CN, Su, YN, Chang, MC, Syu, MH et al. (2005). Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 65: 9089-9098.
41. Imai, H, Saio, M, Nonaka, K, Suwa, T, Umemura, N, Ouyang, GF et al. (2007). Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 98: 416-423.
42. Cheng, WF, Chen, LK, Chen, CA, Chang, MC, Hsiao, PN, Su, YN et al. (2006). Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. Mol Ther 13: 203-210.
43. Chen, CA, Chang, MC, Sun, WZ, Chen, YL, Chiang, YC, Hsieh, CY et al. (2009). Noncarrier naked antigen-specifc DNA vaccine generates potent antigen-specifc immunologic responses and antitumor effects. Gene Ther 16: 776-787.
44. Cheng, WF, Hung, CF, Hsu, KF, Chai, CY, He, L, Polo, JM et al. (2002). Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13: 553-568.
45. Cheng, WF, Hung, CF, Pai, SI, Hsu, KF, He, L, Ling, M et al. (2002). Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 9(6 Pt 2): 675-687.
46. Cheng, WF, Lee, CN, Chang, MC, Su, YN, Chen, CA and Hsieh, CY (2005). Antigen-specifc CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway. Mol Ther 12: 960-968.
47. Roord, ST, de Jager, W, Boon, L, Wulffraat, N, Martens, A, Prakken, B et al. (2008). Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. Blood 111: 5233-5241